Patents by Inventor Thomas R. Bukowski

Thomas R. Bukowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel FGF homologs
    Publication number: 20040096936
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zFGF-5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells and may be used for remodelling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF-5 polypeptides.
    Type: Application
    Filed: October 19, 2001
    Publication date: May 20, 2004
    Applicant: ZymoGenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin, Fenella Raymond, Thomas R. Bukowski, Susan D. Holderman, Birgit Hansen, Paul O. Sheppard
  • FGF homologs
    Patent number: 6518236
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.
    Type: Grant
    Filed: January 13, 1999
    Date of Patent: February 11, 2003
    Assignee: ZymoGenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin, Fenella Raymond, Thomas R. Bukowski, Susan D. Holderman, Birgit Hansen, Paul O. Sheppard
  • Novel FGF homologs
    Publication number: 20030008351
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for ZFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.
    Type: Application
    Filed: February 21, 2002
    Publication date: January 9, 2003
    Applicant: ZymoGenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin, Fenella C. Raymond, Thomas R. Bukowski, Susan D. Holderman, Paul O. Sheppard
  • FGF Homologs
    Patent number: 6352971
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zFGF-5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells and may be used for remodelling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF-5 polypeptides.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: March 5, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin, Fenella Raymond, Thomas R. Bukowski, Susan D. Holderman, Birgit Hansen, Paul O. Sheppard
  • FGF homologs
    Patent number: 5989866
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zFGF-5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells and may be used for remodelling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF-5 polypeptides.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: November 23, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin, Fenella Raymond, Thomas R. Bukowski, Susan D. Holderman, Birgit Hansen, Paul O. Sheppard
  • Production of GAD65 in methylotrophic yeast
    Patent number: 5965389
    Abstract: Methylotrophic yeast are used for high-level expression of GAD65 that makes the production of GAD65 feasible on an industrial scale. A methanol-inducible promoter from, for example, an alcohol oxidase gene, such as Pichia pastoris AOX1, can be used to regulate GAD65 expression. The recombinant GAD65 has high specific activity and retains antigenic characteristics of the native molecule that are essential to immunological assays and therapeutic protocols.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: October 12, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Christopher K. Raymond, Thomas R. Bukowski, Paul D. Bishop